Hydroquinone
CAS 123-31-9
Hydroquinone (CAS 123-31-9) is a Phase 4 pharmaceutical compound with 14 bioactivity targets and 55 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 24320.420714285712 nM | 124 | - |
| - | IC50 | 16347.240967741935 nM | 30 | - |
| - | Ki | 15413.20125 nM | 16 | - |
| - | AC50 | 12323.166666666666 nM | 3 | - |
| - | MIC | 50 ug.mL-1 | 2 | - |
| - | EC50 | 57000 nM | 1 | - |
| - | IC50 | 3 ug.mL-1 | 1 | - |
| Carbonic anhydrase 2 Enzyme |
Ki | 7.05 | - | Homo sapiens |
| Carbonic anhydrase 1 Enzyme |
Ki | 4.97 | - | Homo sapiens |
| Carbonic anhydrase 4 Enzyme |
Ki | 4.97 | - | Homo sapiens |
| Carbonic anhydrase 9 Enzyme |
Ki | 4.49 | - | Homo sapiens |
| Carbonic anhydrase 12 Enzyme |
Ki | 5.11 | - | Homo sapiens |
| Carbonic anhydrase 5A, mitochondrial Enzyme |
Ki | 4.85 | - | Homo sapiens |
| Carbonic anhydrase 5B, mitochondrial Enzyme |
Ki | 4.9 | - | Homo sapiens |
| Carbonic anhydrase 3 Enzyme |
Ki | 5.09 | - | Homo sapiens |
| Carbonic anhydrase 14 Enzyme |
Ki | 4.38 | - | Homo sapiens |
| Carbonic anhydrase 13 Enzyme |
Ki | 4.13 | - | Mus musculus |
| Acetylcholinesterase Enzyme |
Ki | 8.91 | - | Electrophorus electricus |
| Polyphenol oxidase 2 Enzyme |
IC50 | 5.01 | - | Agaricus bisporus |
| Carbonic anhydrase 15 Enzyme |
Ki | 4.97 | - | Mus musculus |
| Carbonic anhydrase Enzyme |
Ki | 5.23 | - | Dicentrarchus labrax |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Squamous cell carcinoma of skin | 42 | 206.853 | 10041834 |
| Skin atrophy | 21 | 105.965 | 10040799 |
| Ochronosis | 9 | 80.572 | 10051253 |
| Neoplasm skin | 14 | 79.021 | 10029098 |
| Product use in unapproved indication | 25 | 37.575 | 10076476 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| HYDROQUINONE | 5509 | SU | MTHSPL |
| Hydroquinone | 5509 | SU | MTHSPL |
| hydroquinone | 5509 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Hydroquinone used for in pharmaceutical contexts?
Hydroquinone (CAS 123-31-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Hydroquinone?
Hydroquinone has 55 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Squamous cell carcinoma of skin, Skin atrophy, Ochronosis, Neoplasm skin, Product use in unapproved indication. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Hydroquinone also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Hydroquinone with EU status "prohibited".
What clinical phase is Hydroquinone in?
Hydroquinone is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Hydroquinone?
Hydroquinone has 21 bioactivity rows in this page query. Rendered target entries include Carbonic anhydrase 2, Carbonic anhydrase 1, Carbonic anhydrase 4, Carbonic anhydrase 9, Carbonic anhydrase 12.